MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results
MYMDDelisted Stock | USD 1.82 0.02 1.09% |
About 61% of MyMD Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in MyMD Pharmaceuticals suggests that many traders are alarmed regarding MyMD Pharmaceuticals' prospects. The current market sentiment, together with MyMD Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use MyMD Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
MyMD |
MyMD Pharmaceuticals, Inc. , a clinical stage pharmaceutical company committed to developing novel therapies
Read at businesswire.com
MyMD Pharmaceuticals Fundamental Analysis
We analyze MyMD Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MyMD Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MyMD Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Retained Earnings
Retained Earnings Comparative Analysis
MyMD Pharmaceuticals is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
MyMD Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MyMD Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of MyMD Pharmaceuticals could also be used in its relative valuation, which is a method of valuing MyMD Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
MyMD Pharmaceuticals Related Equities
UBX | Unity Biotechnology | 4.17 | ||||
RXRX | Recursion Pharmaceuticals | 3.58 | ||||
GOVX | GeoVax Labs | 2.26 | ||||
DSGN | Design Therapeutics | 2.25 | ||||
BOLT | Bolt Biotherapeutics | 2.00 | ||||
KZR | Kezar Life | 1.86 | ||||
NVCT | Nuvectis Pharma | 1.53 | ||||
XBIO | Xenetic Biosciences | 1.47 | ||||
REPL | Replimune | 1.30 | ||||
LYRA | Lyra Therapeutics | 1.18 | ||||
GOSS | Gossamer Bio | 0.48 | ||||
REVB | Revelation Biosciences | 0.33 | ||||
AVIR | Atea Pharmaceuticals | 0.31 | ||||
PASG | Passage Bio | 0.15 | ||||
SRZN | Surrozen | 0.08 | ||||
NBY | NovaBay Pharmaceuticals | 0 | ||||
KRON | Kronos Bio | 0 | ||||
LGND | Ligand Pharmaceuticals | 0.37 | ||||
KROS | Keros Therapeutics | 1.02 | ||||
LYEL | Lyell Immunopharma | 1.61 | ||||
ORIC | Oric Pharmaceuticals | 1.68 | ||||
LRMR | Larimar Therapeutics | 2.38 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Consideration for investing in MyMD Stock
If you are still planning to invest in MyMD Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MyMD Pharmaceuticals' history and understand the potential risks before investing.
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
CEOs Directory Screen CEOs from public companies around the world | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |